News
Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...
The Department of Health investigates an incident involving a private doctor administering COVID-19 vaccines that exceeded ...
Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...
The FDA has approved new versions of Pfizer/BioNTech's Comirnaty and Moderna's Spikevax COVID-19 vaccines that target the Omicron KP.2 strain of SARS-CoV-2 which was dominant in the US in recent ...
Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza.
Notable among these examples is that of a 16-year-old boy, who was found with a large number of vaporiser pods in his home.
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...
As of June 22, there were 1,648 cases of the new variant reported across 38 countries. In the UK, the latest data by the UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results